Women’s Health News

Women reported a significantly lower frequency of moderate to severe menopausal vasomotor symptoms while taking elinzanetant vs. placebo, according to the results of a phase 3 trial.

On March 18, President Joe Biden signed an executive order and announced new actions to improve women’s health research and innovation in the U.S., according to a White House press release.

Since the Dobbs decision in June 2022, mifepristone has been heavily discussed within legal landscapes regarding its safety, efficacy and availability for women seeking medication abortion.

Risks for preterm birth overall and by gestational age varied for women across all nativity, ethnicity and racial identities, according to a retrospective national cohort study published in JAMA Network Open.

A web-based educational aid significantly improved decision-making for pregnant women considering tubal sterilization after delivery vs. usual care, researchers reported in JAMA Network Open.

During pesticide spray season, urinary glyphosate concentrations were significantly higher in pregnant women living near agriculture fields vs. pregnant women who lived 0.5 km or farther from agriculture fields, according to a study.

Women who underwent radiofrequency ablation for uterine fibroids had similar rates of full-term pregnancy, vaginal delivery and miscarriage as observed with myomectomy, researchers reported in Obstetrics & Gynecology.

Once-daily oral elinzanetant was associated with significantly reduced frequency of moderate to severe menopausal vasomotor symptoms compared with placebo, according to topline results from the OASIS 3 study.

During the COVID-19 pandemic, same-day discharges following minimally invasive hysterectomy for benign indications increased without also increasing postoperative hospital readmission, researchers reported.

Researchers observed no superiority in future reproductive or obstetric outcomes with double-layer vs. single-layer uterine closure after a first cesarean section.